OmniAb, Inc. (OABI)

In the past six months, OmniAb, Inc. reported Q2, Q1, and Q3 losses, lagging revenue estimates, but Q4 loss topped revenue estimates. The company also reported double-digit percentage growth in active partners and programs in 2024. In September 2025, OmniAb's price target was increased by 10.30% to $8.84 by Fintel. There were reports of insider buying, including a director purchasing 125,750 shares in March 2025. OABI's weekly volatility has been stable, and it has not had significant price volatility compared to the US market; however, institutional investors endured losses after the company's share price fell by 13% in a week in December 2024.

Information directly detailing the demand seasonality for OmniAb, Inc.'s products and services is not explicitly available. However, the company's business model, which relies on licensing fees, service contracts, milestone payments, and royalties from drug development programs, suggests that its revenue streams may not be subject to typical seasonal fluctuations. OmniAb's revenues are described as "predictably lumpy," stemming from upfront or annual payments, payments for research services, and downstream milestone and royalty payments, which are dependent on the progress and success of its partners' drug development programs.

OmniAb, Inc. is a biotechnology company specializing in the discovery and development of therapeutic antibodies, operating within the healthcare sector and focusing on commercial physical and biological research. The company's core business revolves around licensing its proprietary antibody discovery research technology to pharmaceutical and biotechnology companies, as well as academic institutions, to facilitate the development of innovative therapeutics. OmniAb's major products and platforms include OmniRat, a transgenic rat platform designed for generating fully human antibodies; OmniChicken, a platform utilizing the chicken immune system to produce diverse antibody repertoires; OmniMouse, another transgenic animal platform for generating human antibodies; OmniFlic, a platform optimized for the generation of bispecific antibodies; OmniClic, a bispecific chicken platform for discovering bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics; OmnidAb, an in vivo platform for discovering single-domain antibodies; OmniDeep, a suite of AI and machine learning tools; and custom antibody development services.

OmniAb, Inc. operates globally, serving pharmaceutical and biotechnology companies by licensing its discovery research technology to partners in the United States, Europe, Japan, China, and Canada. The company maintains research facilities in North America and Europe, with its corporate headquarters and primary research and development facilities located in Emeryville, California. Additionally, the company leases research and development space in Durham, North Carolina, and Tucson, Arizona.

OmniAb's brand reputation is characterized by its innovative platforms and strategic partnerships, recognized for launching new antibody discovery platforms and expanding its global footprint through strategic collaborations. The company is seen as a leader in antibody discovery platforms, leveraging cutting-edge technologies, and its commitment to sustainability initiatives contributes positively to its reputation. However, financial performance has presented some challenges, with revenue decreasing and losses increasing in 2024, and missing revenue estimates in recent quarters, which could impact investor confidence. Despite these financial hurdles, analysts have given OABI a "Strong Buy" consensus rating with a significant projected price target increase.

Institutional investors hold a significant stake in OmniAb, Inc., possessing 55% of the company's shares, with the top 13 shareholders owning 52% of the company. Overall, institutional ownership accounts for 55.82%, while individuals own 7.91% and other shareholders hold 10.81%, with 23.71% categorized as unknown. Major institutional owners include State Street Corp., SEI Investments Co., and Manulife Financial Corp. The geographical origin of shareholders indicates that 62.26% are from the United States.